Apexigen is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is currently in Phase 2 clinical development, and also includes several preclinical stage immuno-oncology programs.

Apexigen’s APXiMAB™ technology platform was used to enable the discovery of multiple protein therapeutic drug candidates against challenging disease targets. Apexigen has out-licensed five programs for the development of product candidates that were discovered using the APXiMAB platform. One of these out-licensed programs has yielded a product that is commercially available. The other out-licensed product candidates are advancing in clinical development.

Management Team

Board of Directors

Scientific Advisors